Who is in charge of assessing therapeutic drug monitoring? The case of imatinib

The Lancet Oncology

Volumn 12, Issue 1, 2011, Pages 9-11

  Buclin, Thierry ^a   Widmer, Nicolas ^a   Biollaz, Jerome ^a   Decosterd, Laurent A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MONITORING; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; NEOPLASM; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DRUG INDUSTRY; DRUG MONITORING; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 78650715307     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70258-8     Document Type: Letter

References (10)

1. Warning letter to Novartis pharmaceuticals corporation US Food and Drug Administration, (accessed Oct 10, 2010). http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm210191.htm.
2. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028. for the IRIS (International Randomized Interferon vs STI571) Study Group.
3. Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib and the role of α1-acid glycoprotein. Br J Clin Pharmacol 2006, 62:97-112.
4. Petain A, Kattygnarath D, Azard J, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 2008, 14:7102-7109. for the Innovative Therapies with Children with Cancer European consortium.
5. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009, 27:3141-3147.
6. Widmer N, Decosterd LA, Leyvraz S, et al. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 2008, 98:1633-1640.
7. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009, 23:1537-1544.
8. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010, 8(suppl 2):S1-S41.
9. Glasziou P, Irwig L, Mant D Monitoring in chronic disease: a rational approach. BMJ 2005, 330:644-648.
10. Klümpen HJ, Samer CF, Mathijssen RH, Schellens JH, Gurney H Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 2010, published online Sept 25. 10.1016/j.ctrv.2010.08.006.